Absci Corp. (NASDAQ:ABSI) is one of the 10 most shorted penny stocks to buy.
As of the April 23 closing, the stock carries a strongly bullish consensus sentiment. Of the 7 analysts who provided coverage, 6 assigned Buy ratings and 1 gave a Hold call. It has a median 1-year target price of $7.64, leading to an upside of more than 92% at the current level. Such consensus views make for a highly compelling story around this penny stock, which has faced significant short interest recently.
everything possible/Shutterstock.com
Back on March 24, Absci Corp. (NASDAQ:ABSI) announced an advisory board on endometriosis to help with clinical research in ABS-201, which is their anti-prolactin receptor antibody drug program. These include experts from Yale, Duke, UCSF, and the Mayo Clinic, who will provide insights for the development of this novel antibody treatment.
Endometriosis is a chronic inflammatory disorder that affects about 190 million people across the world. The current therapies available are hormonal therapies, and unfortunately, they do not treat the actual disease itself. With this anti-prolactin antibody, there could be an end to this disorder without affecting one’s ovulation and fertility, since this therapy will target a different pathway.
In an interview, the founder and CEO of Absci, Sean McClain, mentioned that current approved therapies utilize hormone suppression, leaving the patient to choose between either managing her disease or her ability to conceive a child. But ABS-201 treats patients differently from the usual approach. The company is working towards starting its Phase 2 trials by the fourth quarter of 2026, with interim data expected in the second half of 2027.
Absci Corporation (NASDAQ:ABSI) is engaged in the development of several antibody therapeutics. It offers four different types of therapeutics, which include ABS-101, which is in phase 1 of the clinical trial, ABS-201, which is in phase 1/2a clinical trial, ABS-301, and ABS-501. It has partnership agreements with various organizations, including Memorial Sloan Kettering Cancer Center, Oracle Corporation, Advanced Micro Devices, Twist Bioscience, and others.
While we acknowledge the risk and potential of ABSI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABSI and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center